From plush figures to digital pets, a new class of AI toys is emerging — built not around screens or sensors, but around memory, language and emotional awareness
Updated
March 17, 2026 1:02 AM
Spielwarenmesse toy fair. PHOTO: SPIELWARENMESSE
Spielwarenmesse in Nuremberg is the global meeting point for the toy industry, where brands and designers preview what will shape how children play and learn next. At this year’s fair, one message stood out clearly: toys are no longer built just to entertain, but to listen, respond and grow with children. Tuya Smart, a global AI cloud platform company, used the event to show how AI-powered toys are turning familiar formats into interactive companions that can talk, react emotionally and adapt over time.
The company’s central argument was simple but far-reaching. The next generation of artificial intelligence toys will not be defined by motors, sensors or screens alone, but by how well they understand human behavior. Instead of being single-function objects, smart toys for children are becoming systems that combine language models, emotion recognition and memory to support ongoing interaction.
One of the most talked-about examples was Tuya Smart’s Nebula Plush AI Toy. At first glance, it looks like a soft, expressive plush figure. Inside, it uses emotional recognition to change its LED facial expressions in real time. If a child sounds sad or excited, the toy’s eyes respond visually. It supports natural conversation, reacts to hugs and touch and combines storytelling, news-style updates and interactive games. Over time, it builds memory, allowing it to behave less like a gadget and more like an interactive AI toy that recalls past interactions.
Another example was Walulu, also developed using Tuya’s AI toy platform. Walulu is an AI pet built around personalization. It can detect up to 19 emotional states and speak more than 60 languages. It connects to major large language models such as ChatGPT, Gemini, DeepSeek, Qwen and Doubao. Through simple app-based controls, users choose traits like cheerful, quiet, curious or thoughtful. Those choices shape how Walulu talks and reacts. Instead of repeating scripts, it adjusts its tone and behavior over time. The result is not a novelty item, but an emotionally responsive AI toy that feels consistent in daily use.
Tuya also showed how educational AI toys can extend into learning and exploration. Its AI Learning Camera blends computer vision with interactive content. When it recognizes an object, it links it to cultural and learning material. If a child points it at a foreign word, it offers real-time pronunciation and translation. It can also turn drawings into digital artwork, encouraging active creativity rather than passive screen time. In this sense, AI toys for kids are becoming tools for learning as much as play.
These products point to a larger strategy. Tuya is not just making toys — it is building the AI toy development platform behind them. Through its AI Toy Solution, developers can design a toy’s personality, memory logic and behavior without training models from scratch. The system integrates with leading AI models and supports multi-turn conversation and emotional feedback, turning standard hardware into responsive AI companions.
The platform supports multiple development paths. Brands can use ready-to-market OEM solutions, add AI to existing products or build custom toys around their own characters. Plush toys, robots, educational tools and wearables can all become AI-powered toys without changing their physical design.
Because these products are made for children and families, safety is built in. Tuya’s system includes parental controls, conversation history review and content management. It supports standards such as GDPR and CCPA with encryption and data localization.
From a business standpoint, Tuya’s pitch is speed and scale. The company says its AI toy infrastructure can cut development time by more than half and reduce R&D costs by up to 50 percent. Its AIoT network spans over 200 countries and supports more than 60 languages, making global deployment of AI toys easier.
What emerged at Spielwarenmesse 2026 was not just a lineup of smart gadgets, but a clear shift in the category. AI toys are evolving into emotionally aware systems that talk, listen, remember and adapt. Their value lies not in sounding clever, but in fitting naturally into everyday life.
The fair did not present AI toys as a distant future. It showed them as products already entering the mainstream. The real question now is not whether toys will use AI, but how carefully that intelligence is designed for children.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.